Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from 4DMedical Ltd ( (AU:4DX) ) is now available.
S&P Dow Jones Indices will remove Insignia Financial Limited from the S&P/ASX 200 Index following its proposed acquisition by Daintree BidCo Pty Ltd, with the change scheduled to take effect before trading opens on 20 April 2026. 4DMedical Limited will be added to the benchmark in Insignia’s place, elevating the medtech group into the ranks of Australia’s top 200 listed companies and potentially broadening its investor base and index-linked fund exposure.
The most recent analyst rating on (AU:4DX) stock is a Sell with a A$3.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Ltd is an Australian medical technology company that develops advanced imaging solutions for respiratory health. Listed on the ASX under the ticker 4DX, it focuses on lung imaging and ventilation analysis, targeting clinicians and healthcare providers seeking more precise diagnostic tools for pulmonary disease management.
Average Trading Volume: 7,618,808
Technical Sentiment Signal: Buy
Current Market Cap: A$4.01B
For a thorough assessment of 4DX stock, go to TipRanks’ Stock Analysis page.